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Abstract
Background: Few data are available on long-term follow-up of drug-eluting stents in the 
treatment of chronic total occlusion (CTO). The LEADERS CTO sub-study compared the 
long-term results in CTO and non-CTO lesions of a Biolimus A9™-eluting stent (BES) with 
a sirolimus-eluting stent (SES).
Methods: Among 1,707 patients enrolled in the prospective, multi-center, all-comers LEADERS  
trial, 81 with CTOs were treated with either a BES (n = 45) or a SES (n = 36). The primary 
endpoint was the occurrence of major adverse cardiac events (MACE): cardiac death, myocar-
dial infarction (MI) and clinically-indicated target vessel revascularization (TVR).
Results: At 5 years, the rate of MACE was numerically higher in the CTO group than in 
the non-CTO group (29.6% vs. 23.3%; p = 0.173), with a significant increase in the inci-
dence of target lesion revascularization (TLR) (21.0 vs. 12.6; p = 0.033), but no difference in 
stent thrombosis (ST). Patients with CTO receiving a BES demonstrated a lower incidence 
of MACE (22.2% vs. 38.9%; p = 0.147) with a significant reduction in TLR compared to 
patients receiving a SES (11.1% vs. 33.3%, p = 0.0214) with an incidence similar to that ob-
served in the non-CTO group treated with BES (11.6%). Definite ST at 5 years nearly halved 
in the BES group (4.4% vs. 8.3%, p = 0.478) with no ST in the BES group after the first year 
(0% vs. 8.3%, p for interaction = 0.009).
Conclusions: The use of a BES showed a reduction in MACE, TVR, TLR, and ST over time in 
the CTO subset with similar outcome as for non-CTO lesions. (Cardiol J 2016; 23, 6: 626–636)
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Introduction
Revascularization of chronic total occlusion 
(CTO) is grossly underutilized in patients who un-
dergo percutaneous coronary interventions (PCI) 
[1–3]. The initial success is lower and a high rate 
of re-occlusion burdened the initial experiences 
with balloon angioplasty and bare metal stents 
(BMS) [4, 5]. The introduction of new devices, 
such as dedicated guidewires, low profile balloons, 
or microcatheters [6] has increased the immediate 
success rate, however greater complexity of le-
sions treated may potentially exacerbate the risk. 
Drug-eluting stents (DES) have reduced reste-
nosis and reocclusion when compared with BMS 
[7–11], but a recent publication of long-term data 
still reports worse results than those expected in 
non-CTO lesions [12]. Although second generation 
DES have greater polymer biocompatibility and dif-
ferent mechanical properties than first generation 
paclitaxel- and sirolimus-eluting stents (PES and 
SES), there are few data on long-term results ob-
tained with these devices in patients with CTO [13, 
14] and on the differences with non-CTO lesions 
or CTO lesions treated with first generation DES.
The LEADERS CTO sub-study is a post-hoc 
analysis of a randomized multicenter trial and was 
designed to compare the results after 5 years of 
follow-up of CTO lesions treated with a Biolimus 
A9-eluting stent with abluminal biodegradable 
polymer coating (BES) and a sirolimus-eluting 
permanent polymer stent (SES).
Methods
Study design and population
LEADERS was a prospective, multi-center, 
assessor-blind, non-inferiority trial involving 
12 European centers (Belgium, France, Germany 
[3 centers], Netherlands, Poland, Switzerland 
[2 centers] and the United Kingdom), designed 
to compare the safety and efficacy of a BES with 
a biodegradable polymer (BioMatrix Flex™, 
Biosensors Europe SA, Morges, Switzerland) with 
a SES with durable polymer (Cypher® Select™, 
Cordis, Miami, USA) in a “real world, all-comers” 
patient population. The LEADERS trial study de-
sign is reported elsewhere [15]. The LEADERS 
trial was approved by all institutional Ethics Com-
mittees.
Unlike most other DES studies, CTO was not 
an exclusion criterion. CTO subgroup analysis is 
a post-hoc analysis performed on the LEADERS 
data set. Patients were divided according to the 
presence or absence of pre-procedural CTO, based 
on the pre-procedure angiogram and technical 
details of the intervention. Patients with at least 
one treated CTO lesion were classified as treated 
CTO patients. CTO was defined as a 100% coronary 
artery occlusion, with thrombolysis in myocardial 
infarction (TIMI) flow grade equal to 0 and dura-
tion of minimum 3 months. The occlusion duration 
was either angiographically proven or clinically 
estimated, according to the onset of symptoms or 
the timing of acute coronary events in the territory 
subtended by the CTO artery.
Angiography was analyzed at one core labora-
tory (Cardialysis, Rotterdam, The Netherlands) 
with the assessor blinded to the allocated stent.
Procedures and devices
Biolimus-eluting stents were available in di-
ameters of 2.25, 2.5, 3.0, and 3.5 mm and in lengths 
of 8, 11, 14, 18, 24, and 28 mm. Sirolimus-eluting 
stents were available in diameters of 2.25, 2.5, 
2.75, 3.0, and 3.5 mm and in lengths of 8, 13, 18, 
23, 28, and 33 mm. Both platforms are made of 
stainless steel but BES struts are thinner (120 μm) 
than SES struts (140 μm). The main difference is 
represented by the drug, i.e. biolimus A9 versus 
sirolimus, and polymer used, i.e. a biodegradable 
polylactic acid coating in the BES versus a durable 
polymer covering in the SES.
Balloon angioplasty and stent implantation 
were performed according to standard techniques. 
In the CTO group, either anterograde or retro-
grade recanalization strategies were allowed, no 
restrictions were applied to the material used. 
Full lesion coverage with the index stent was the 
routine strategy.
Before or at the time of the procedure, patients 
were given at least 75 mg of acetylsalicylic acid 
(ASA), 300–600 mg loading dose of clopidogrel, and 
unfractionated heparin in a dose of at least 5,000 IU 
or 70–100 IE/kg. The use of glycoprotein IIb/IIIa 
antagonists was left to the discretion of the 
operator.
All patients were discharged on at least 75 mg 
daily ASA indefinitely and clopidogrel 75 mg daily 
for at least 12 months.
Outcomes
In-hospital adverse events were assessed and 
clinical follow-up was planned up to 5 years.
The primary endpoint was a composite of 
cardiac death, myocardial infarction (MI), and 
clinically indicated target vessel revascularization 
(TVR). The definition of cardiac death included 
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any death due to immediate cardiac cause (e.g., 
MI, low-output failure, fatal arrhythmia), deaths 
related to the procedure, including those related 
to concomitant treatment, unwitnessed death, and 
death of unknown cause. MI was defined using the 
electrocardiographic criteria of the Minnesota code 
manual or as a measurement of creatine kinase 
concentrations to more than double normal, with 
positive concentrations of creatine kinase-MB or 
troponin I or T. TVR was defined as any repeat 
percutaneous intervention or surgical bypass of 
any segment within the entire major coronary ves-
sel proximal and distal to a target lesion, including 
upstream and downstream branches and the target 
lesion itself. Revascularization was regarded as clini-
cally indicated if the stenosis of the treated lesion 
was at least 50% of the lumen diameter on the basis 
of quantitative coronary angiography in the presence 
of ischemic signs or symptoms, or if the diameter 
stenosis was at least 70% irrespective of the pres-
ence or absence of ischemic signs or symptoms.
Secondary endpoints were cardiac death, death 
from any cause, MI, clinically-indicated target le-
sion revascularization (TLR) defined as a repeated 
revascularization due to a stenosis within the stent 
or within a 5 mm border proximal or distal to the 
stent, repeated PCI (re-PCI), any TVR, or stent 
thrombosis (ST) according to the definitions of the 
Academic Research Consortium [16].
Statistical analysis
The statistical design of the LEADERS trial 
is described elsewhere [15].
A stratified post hoc analysis of clinical and 
angiographic outcomes was performed within the 
treated CTO and non-CTO groups, with patients 
compared based on the randomized study stents 
(BES or SES) implanted.
Discrete data were summarized as frequen-
cies (n, %) and compared by Fisher’s exact test. 
Continuous data were expressed as mean ± stand-
ard deviation and compared by Student’s t-test. 
The Cox proportional hazards model was used to 
compare clinical outcomes among groups. Survival 
curves were constructed for time-to-event vari-
ables using Kaplan-Meier estimates, and compared 
by the log-rank test. All p-value and confidence 
intervals are two-sided at 5% level.
Results
A total of 1,707 patients were enrolled in 
the LEADERS trial. Among them 86 had a CTO 
lesion, of which 81 patients were successfully 
treated with either the study or comparator stent 
(45 patients with BES vs. 36 patients with SES). 
The non-CTO group included 1,621 patients, of 
which 809 were treated with BES versus 812 with 
SES (Fig. 1).
Baseline characteristics
Baseline characteristics according to CTO and 
non-CTO group and type of stent implanted in each 
group are shown in Table 1.
There were no major baseline clinical differ-
ences between patients with and without CTOs, 
except for a greater frequency of ST segment 
elevation MI in the non-CTO group and a higher 
incidence of prior MI in the CTO group.
Compared to non-CTO lesions, CTO lesions 
were significantly more complex as reflected by 
greater lesion length with a higher Syntax score, 
resulting in a greater number of stents implanted. 
Within the CTO group, there was a higher num-
ber of lesions treated in the SES group compared 
to the BES group (1.89 ± 1.04 vs. 1.44 ± 0.66; 
Figure 1. Study flow chart; BES — biodegradable polymer biolimus-eluting stents; CTO — chronic total occlusion; 
SES — sirolimus-eluting stent.
628 www.cardiologyjournal.org
Cardiology Journal 2016, Vol. 23, No. 6
p = 0.029), as well as the Syntax score (20.0 ± 8.6 
vs. 15.2 ± 8.7; p = 0.048). No significant differ-
ences were found with regard to stent length and 
number of stents implanted (Table 1).
Angiographic and procedural characteristics 
for the CTO group demonstrate that the right 
coronary artery was more frequently targeted in 
the BES group (Table 2).
CTO versus non-CTO lesions
At 5-year follow-up, the incidence of overall 
major adverse cardiac events (MACE) was similar 
between the CTO and non-CTO groups (29.6% vs. 
23.3%; p = 0.173). Likewise, no significant differ-
ences were found in the rate of cardiac death, MI 
and both clinically-indicated and any TVR (Table 3). 
Clinically-indicated TLR did not show any statisti-
cal significant difference in the CTO and non-CTO 
groups (16% vs. 10.5%; p = 0.13), but the number 
of any TLR was significantly higher in the CTO 
group (Fig. 2A). The incidence of definite ST and 
definite plus probable ST was percentually higher, 
yet not significant in the CTO compared to non-
CTO group (Table 3).
CTO lesions: BES versus SES
Patients with CTO treated with BES had 
a non-significant lower incidence of MACE 
(22.2% vs. 38.9%; HR 0.549, 95% CI 0.243–1.236; 
p = 0.147). With regard to other clinical endpoints, 
such as cardiac death, clinically-indicated TVR and 
TLR, the rate of events was numerically lower in 
Table 1. Baseline characteristics. The groups are divided according to the type of revascularization and 
stent.
Treated CTO (n = 81) No CTO (n = 1621) P: Treated 
CTO vs.  
no CTOBES  
(n = 45)
SES  
(n = 36)
P: BES  
vs. SES
BES  
(n = 809)
SES  
(n = 812)
P: BES  
vs. SES
Age [years] 62.0 ± 10.5 64.9 ± 12.4 0.264 64.7 ± 10.8 64.5 ± 10.6 0.658 0.277
Male 38 (84.4) 27 (75.0) 0.401 602 (74.4) 605 (74.5) 1 0.294
Diabetes 12 (26.7) 5 (13.9) 0.182 210 (26.0) 185 (22.8) 0.148 0.595
Hypertension 28 (62.2) 27 (75.0) 0.242 600 (74.3) 589 (72.7) 0.499 0.303
Hypercholesterolemia 36 (80.0) 27 (75.0) 0.603 522 (64.6) 552 (68.1) 0.141 0.039
Currently smoking 9 (20.0) 9 (25.0) 0.603 195 (24.1) 205 (25.3) 0.604 0.693
Family history 22 (48.9) 19 (52.8) 0.824 316 (39.1) 355 (43.8) 0.055 0.107
Unstable angina 5 (11.1) 5 (13.9) 0.745 185 (22.9) 175 (21.6) 0.550 0.038
STEMI 0 (0) 1 (2.8) 0.444 135 (16.7) 139 (17.1) 0.843 < 0.001
Chronic heart failure 3 (6.7) 1 (2.8) 0.625 20 (2.5) 29 (3.6) 0.246 0.316
Prior MI 24 (53.3) 17 (47.2) 0.658 251 (31.1) 259 (32.0) 0.708 < 0.001
Prior PCI 18 (40.0) 10 (27.8) 0.347 294 (36.4) 300 (37.0) 0.797 0.725
Prior CABG 5 (11.1) 7 (19.4) 0.354 85 (10.5) 100 (12.3) 0.274 0.372
LV ejection fraction [%] 52.8 ± 12.7 57.6 ± 12.9 0.250 56.0 ± 11.2 55.3 ± 12.4 0.360 0.613
Multivessel disease 14 (31.1) 12 (33.3) 1 192 (23.7) 164 (20.2) 0.093 0.040
Number of lesions* 1.44 ± 0.66 1.89 ± 1.04 0.029 1.46 ± 0.69 1.41 ± 0.70 0.113 0.037
Lesions length† [mm] 45.4 ± 24.9 44.4 ± 23.1 0.843 21.0 ± 15.0 19.5 ± 13.5 0.029 < 0.001
Long lesion (> 20 mm) 35 (79.6) 27 (77.1) 1 223 (27.8) 192 (23.9) 0.087 < 0.001
Severe calcification 5 (17.9) 7 (28.0) 0.514 141 (20.8) 147 (22.0) 0.595 0.865
Syntax score 15.2 ± 8.7 20.0 ± 8.6 0.048 13.2 ± 8.6 13.1 ± 8.7 0.819 < 0.001
Number of stents  
implanted per patient‡
2.96 ± 1.46 3.14 ± 1.64 0.597 1.90 ± 1.20 1.80 ± 1.09 0.081 < 0.001
Total stent length [mm] 65.5 ± 37.0 68.0 ± 35.6 0.945 34.2 ± 22.1 33.3 ± 20.6 0.440 < 0.001
N (%) or mean ± standard deviation; *Number of lesions according to Core Lab (QCA data), regardless if they were total occluded pre-pro-
cedure; †Sum of the length of the lesions according to QCA analysis, regardless if they were total occluded; ‡Investigator reported per lesion 
the number of stents and the stent length per used stent. The total number of stents and total stent length per patient is calculated, regardless 
if the lesions were total occluded pre-procedure; BES — biodegradable polymer biolimus-eluting stents; CABG — coronary artery bypass 
grafting; CTO — chronic total occlusion; LV — left ventricular; MI — myocardial ibfarction; PCI — percutaneous coronary intervention;  
SES — sirolimus-eluting stent; STEMI — ST elevation myocardial infarction
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Table 2. Procedural and angiographic characteristics in the CTO group.
BES (n = 45) SES (n = 36) P: BES vs. SES
CTO lesion coronary artery:
Left main 0 (0) 0 (0) NA
Left anterior descending 15 (33.3) 13 (36.1) 0.818
Left circumflex 7 (15.6) 12 (33.3) 0.071
Right coronary artery 23 (51.1) 9 (25.0) 0.023
Bypass graft 0 (0) 2 (5.6) 0.194
Presence of stump 27 (60) 17 (47.2) 0.251
Bridging collateral 14 (31.1) 9 (25.0) 0.544
Retrograde filling 23 (51.1) 21 (58.3) 0.517
Anterograde approach 44 (97.8) 36 (100) NA
Bilateral injection 10 (22.2) 9 (25.0) 0.769
Number of stents implanted 2.36 ± 1.40 2.00 ± 1.01 0.205
Total stent length [mm] 55.5 ± 34.6 46.3 ± 25.3 0.194
RVD [mm]:
In-stent 2.63 ± 0.53 2.59 ± 0.45 0.751
In-segment 2.54 ± 0.58 2.46 ± 0.49 0.501
MLD post-procedure [mm]:
In-stent 2.10 ± 0.66 2.11 ±0.53 0.985
In-segment 1.79 ± 0.62 1.78 ±0.58 0.944
MLA post procedure [mm2]:
In-stent 3.59 ± 1.87 3.37 ± 1.58 0.585
In-segment 2.66 ± 1.58 2.54 ± 1.53 0.730
N (%) or mean ± standard deviation; CTO — chronic total occlusion; BES — biodegradable polymer biolimus-eluting stents; SES — sirolimus- 
eluting stent; NA — not assessed; RVD — reference vessel diameter; MLD — minimal lumen diameter; MLA — minimal lumen area
Figure 2. A. Kaplan-Meier curves show the incidence of target lesion revascularization (TLR) in chronic total occlusion 
(CTO) group vs. non-CTO group; B. Kaplan-Meier curves show the incidence of TLR within the CTO group between 
biodegradable polymer biolimus-eluting and sirolimus-eluting stents (BES and SES); HR — hazard ratio; CI — confi-
dence interval. 
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the BES, while the percentage of MI was slightly 
higher (Table 3). The incidence of clinically-indi-
cated TLRs was halved in the BES group (11% vs. 
22%; HR 0.468, 95% CI 0.153–1.433; p = 0.184). 
However, all TLRs had a significantly higher rate in 
the patients receiving a SES (Fig. 2B). Of interest, 
in the long-term follow-up the rate of any TLR was 
similar between the BES CTO group and overall 
non-CTO group (11.1% vs. 12.6%). Moreover, the 
use of a BES in the CTO group reduced by almost 
two thirds the risk of any TVR (HR 0.326, 95% CI 
0.113–0.942; p = 0.038) and any repeated PCI (HR 
0.350, 95% CI 0.141–0.870; p = 0.024).
The incidence of definite ST was nearly halved 
in the BES group (4.4% vs. 8.3%; HR 0.523, 95% CI 
0.087–3.132; p = 0.478). These results were also 
maintained regardless of dual antiplatelet therapy 
compliance (Table 4).
However, although BES had a higher rate of 
early (≤ 30 days) definite ST (4.4% vs. 0%), no 
events were recorded in the late and very late 
period. Definite ST occurred more frequently in 
the very late period for the SES (p for interaction 
Table 4. All stent thrombosis (ST) and dual antiplatelet (DAPT) discontinuation (d/c) for chronic total 
occlusion (CTO) patients.
Overall population† BES (n = 45) SES (n = 36) P: BES vs. SES*
9 months 2 (4.4%) 0 (0%) 0.500
1 year 2 (4.4%) 0 (0%) 0.500
2 years 2 (4.4%) 2 (5.6%) 1
3 years 2 (4.4%) 3 (8.3%) 0.651
4 years 2 (4.4%) 3 (8.3%) 0.651
5 years 2 (4.4%) 3 (8.3%) 0.651
Patients who d/c DAPT < 12 months‡ BES (n = 10) SES (n = 11) P: BES vs. SES*
9 months 0 (0%) 0 (0%) NA
1 year 0 (0%) 0 (0%) NA
2 years 0 (0%) 1 (9.1%) 1
3 years 0 (0%) 2 (18.2%) 0.476
4 years 0 (0%) 2 (18.2%) 0.476
5 years 0 (0%) 2 (18.2%) 0.476
Patients who d/c DAPT ≥ 12 months‡ BES (n = 31) SES (n = 23) P: BES vs. SES*
9 months 0 (0%) 0 (0%) NA
1 year 0 (0%) 0 (0%) NA
2 years 0 (0%) 1 (4.3%) 0.426
3 years 0 (0%) 1 (4.3%) 0.426
4 years 0 (0%) 1 (4.3%) 0.426
5 years 0 (0%) 1 (4.3%) 0.426
*Fisher’s exact test; †All ST are reported, regardless if patient discontinued DAPT and if the ST took place before or after d/c DAPT; ‡Only  
reported if the ST took place after date of d/c DAPT; BES — biodegradable polymer biolimus-eluting stents; NA — not assessed; SES —  
sirolimus-eluting stent
= 0.009). The same trend was also found in the 
30 days landmark analysis for MACE, significantly 
lower between 30 days and 5 years in the BES group 
(p for interaction = 0.042) (Fig. 3).
Discussion
Patients with CTO are often denied angioplasty 
because the immediate success rate is lower than 
in conventional PCI [17, 18] and the long-term du-
rability is questioned. Limited data are available for 
comparison of long-term follow-up in CTO and non-
CTO patients. In the j-Cypher registry [19], 1,210 
patients with CTO (defined as complete obstruction 
with TIMI flow grade 0 or 1 and an estimated dura-
tion > 1 month) were compared to 9,549 patients 
who underwent PCI on a non-occlusive lesion or 
a recent occlusion. After 5 years of follow-up, the rate 
of TLR was significantly higher if a CTO lesion was 
treated. However, the incidence of all-cause death and 
cardiac death was similar between CTO and non-CTO 
patients. This study confirms the higher incidence of 
late events, especially TLR, in CTO patients treated 
www.cardiologyjournal.org 633
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Figure 3. Landmark analysis at 30 days for major ad-
verse cardiac events (MACE); BES — biodegradable 
polymer biolimus-eluting stents; CI — confidence inter-
val; HR — hazard ratio; SES — sirolimus-eluting stent.
with SES. The similar outcome observed in CTO 
and non-CTO groups treated with BES suggests 
that second generation DES should be preferred in 
these complex lesions to preserve the clinical benefit 
conferred by a successful CTO recanalization. Multi-
ple registries have indicated that a restored patency 
of a complete occlusion may translate into a greater 
clinical benefit than treatment of other non-occlusive 
lesions in stable syndromes [20–22]. ST, especially 
in the late and very late period, represents one of 
the main limitations of DES [23–25]. In our study, 
the overall incidence of all ST and of definite ST 
was similar between the CTO and non-CTO groups. 
These data are in line with the findings of the j-Cypher 
registry where the definite/probable ST did not differ 
according to the groups. However, in that study, the 
only device employed was a SES.
In our study, we tested two different DES 
platforms, from polymers and type of drug eluted 
to mechanical properties. In recent studies com-
paring first versus second generation DES for the 
treatment of CTOs [10, 11], a favorable trend was 
observed for second generation DES in short-
term follow-up. These promising results were 
also confirmed by our study. In fact, in the CTO 
lesion subset, our data showed a notable reduction 
of events in favor of the biodegradable polymer 
Biolimus A9-coated stent with a higher reduction 
mainly in the long-term follow-up, equalizing the 
outcome between CTO and non-CTO groups.
This represents one of the main findings of our 
study. In fact, initial experiences in the POBA/BMS 
era showed that outcome of CTO was worse than 
non-CTO lesions [26]. This worse outcome was 
improved but not fully corrected by the introduc-
tion of first generation DES [27].
Several factors may explain these results. 
Sirolimus-eluting stents show histologic evidence 
of poor biocompatibility with hypereosinophilic 
infiltrates [28] and slow incomplete strut coverage 
which has been confirmed with OCT [29]. Evagi-
nations between struts are a quite specific feature 
of the Cypher stent and a 9-month OCT substudy 
of LEADERS was the first to show a difference in 
strut coverage between BES and SES [30], with 
late catch-up shown at 2 years [31]. The rigidity 
and great thickness of Cypher also predispose 
this stent to late fracture, often associated to 
restenosis and re-occlusion. CTO recanalization 
is associated with the frequent use of long stents 
in vessels with most treatments performed in 
the right coronary artery, a vessel characterized 
by large systo-diastolic excursions. A DES with 
a bioabsorbable polymer has the advantage of 
the polymer gradually degrading and eventually 
disappearing over the course of several months, 
limiting the risk of the late thrombotic events in 
the durable polymer group, especially in complex 
lesions, such as the CTOs.
Limitation of the study
Our study has several limitations. First, the 
LEADERS CTO study, as a post-hoc analysis of 
a randomized controlled trial, was not powered to 
test the difference between CTO and non-CTO 
groups. Although the trial was undertaken in 10 
European centers where high volume PCI proce-
dures were performed by experienced operators 
using modern approaches, patients with at least one 
CTO treated were less than 5% of all the lesions 
treated. The lack of sub-randomization for CTO 
explains some discrepancies in the basal charac-
teristics of the SES and BES groups but the fact 
lesions come from an all-comers registry improves 
homogeneity, making the groups more comparable 
and the selection process more rigorous than in 
other retrospective registries.
The main strength of this sub-study is rep-
resented by the confirmation of the type of lesion 
treated by an independent Core Lab, with nearly 
complete, well documented and fully monitored 
follow-up.
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Conclusions
Chronic total occlusion subgroup of the 
LEADERS all-comers trial showed that BES may 
reduce at 5-year follow-up MACE, TVR, TLR and 
ST when compared to SES. For ST, the benefit of 
DES with biodegradable polymer seems to emerge 
in the late and very late phase, after the polymer 
is fully degraded.
These results of the CTO group are consist-
ent with the overall trial but tested in a small 
subgroup and a larger trial is needed to explore 
these hypotheses.
Moreover, our data suggest that patients with 
a successful recanalization of a CTO lesion with 
BES may have similar outcome to patients without 
CTO treated with PCI, encouraging a more liberal 
use of PCI in CTOs.
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